Judge Rejects Novartis’ Request to Speed Up Hearing in 340B Contract Pharmacy Lawsuit

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies

A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.

Read More »

News Alert: New Senate Bill Would Let HRSA Audit 340B Providers to See How They Use 340B Net Income

Senator Mike Braun (R-IN) has introduced legislation to let the government audit 340B entities to determine how they use net income from 340B savings.

U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.

Please Login or Become

Read More »

Parties at Center of Contract Pharmacy Standoff React to HHS OIG Referral

HRSA's decision to refer six drug manufacturers to the HHS OIG has elicited a variety of reactions.

The decision by the U.S. Health Resources & Services Administration (HRSA) to refer six drug manufacturers to the U.S. Health and Human Services Department of the Office of The Inspector General (HHS OIG) for refusing to offer 340B discounts to

Read More »

Starting Next Month, HRSA Plans to Audit Some 340B Entities Onsite for First Time Since Pandemic

HRSA says it may resume some onsite audits of 340B covered entities as early as next month, sparking concerns among some providers already battling the fallout from the Delta variant of COVID-19.

The U.S. Health Resources and Services Administration (HRSA) says it plans to resume some onsite 340B compliance audits of covered entities starting in October.

Please Login or Become a Paid Subscriber to View this Content

Read More »

Hospitals Urge CMS To Abandon Medicare Part B Cuts While PhRMA Presses For More Action

Hospital trade groups have lodged strong objections to CMS's proposal to maintain deep Medicare Part B reimbursement cuts, while PhRMA is suggesting even further 340B reforms.

Hospital trade groups are lodging strong objections to maintaining steep cuts in Medicare Part B reimbursement as part of the Fiscal Year 2022 final rule for the hospital outpatient prospective payment system (OPPS), while the trade group for brand name

Read More »

Breaking: HRSA Refers Six Drug Companies to HHS OIG For Refusing to Offer Discounts

HRSA has referred six drug manufacturers to the HHS Office of Inspector General for refusing to offer 340B discounts in the contract pharmacy setting.

The U.S. Health Resources & Services Administration (HRSA) today referred six drug manufacturers to the U.S. Health and Human Services Department of the Office of the Inspector General (OIG) regarding their refusal to offer 340B program discounts to 340B covered

Read More »

House GOP Effort to Amend 340B Falls Short in Key Committee

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to crucial budget legislation.

U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to budget legislation integral to enacting congressional Democrats and the Biden administration’s Build Back Better plan.

Please Login or

Read More »

Judge Schedules Joint Hearing in Novartis and United Therapeutics’ 340B Contract Pharmacy Cases

U.S. District Judge Dabney Friedrich scheduled an Oct. 12 joint hearing on pending motions in drug manufacturers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

A federal district judge in Washington, D.C., yesterday scheduled an Oct. 12 joint hearing on pending motions in drug manufacturers’ Novartis and United Therapeutics’ 340B contract pharmacy lawsuits.

Please Login or Become a Paid Subscriber to

Read More »

Sanofi Reaches Out to 340B Entities that Complained to HRSA About its Contract Pharmacy Restrictions

Sanofi has sent letters to 340B covered entities that have complained to HRSA about the drug manufacturer's denials of 340B pricing on drugs shipped to contract pharmacies.

Drug manufacturer Sanofi has sent letters to 340B covered entities that have complained to federal authorities about its denials of 340B pricing on drugs shipped to contract pharmacies, covered entity representatives say.

Please Login or Become

Read More »

Biden Administration Moves a Step Closer to Trashing Trump’s 340B Health Center Insulin/EpiPen Rule

Former President Trump signed an executive order in July 2020 directing HHS to limit what 340B health centers can charge patients for insulin and EpiPen-type devices.

The dumping of a controversial Trump administration rule limiting what 340B health centers can charge patients for insulin and EpiPen-type devices took a big step closer to being finalized last week.

Please Login or Become a

Read More »
Generic selectors
Exact matches only
Search in title
Search in content